Compare · LUCY vs RXST
LUCY vs RXST
Side-by-side comparison of Innovative Eyewear Inc. (LUCY) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCY and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- RXST is the larger of the two at $210.1M, about 32.9x LUCY ($6.4M).
- LUCY has been more active in the news (10 items in the past 4 weeks vs 6 for RXST).
- RXST has more recent analyst coverage (25 ratings vs 0 for LUCY).
- Company
- Innovative Eyewear Inc.
- RxSight Inc.
- Price
- -
- -
- Market cap
- $6.4M
- $210.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2021
- News (4w)
- 10
- 6
- Recent ratings
- 0
- 25
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest LUCY
- Innovative Eyewear's Lucyd Armor® Smart Safety Glasses Now Certified for Australia and New Zealand
- Innovative Eyewear Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Innovative Eyewear Inc.
- SEC Form 10-Q filed by Innovative Eyewear Inc.
- Innovative Eyewear Reports Third-Quarter 2026 Results
- Chief Financial Officer Gayle Oswald was granted 60,000 shares, increasing direct ownership by 303% to 79,798 units (SEC Form 4)
- Chief AI & Growth Officer Dabrowski Konrad was granted 50,000 shares, increasing direct ownership by 122% to 90,977 units (SEC Form 4)
- Chief Operating Officer Abondano Joaquin was granted 90,000 shares, increasing direct ownership by 360% to 115,012 units (SEC Form 4)
- Chief Executive Officer Gross Harrison R. was granted 100,000 shares, increasing direct ownership by 284% to 135,195 units (SEC Form 4)
- Chief Technology Officer Cohen David Eric was granted 60,000 shares, increasing direct ownership by 254% to 83,622 units (SEC Form 4)
Latest RXST
- SEC Form SCHEDULE 13G filed by RxSight Inc.
- SEC Form S-8 filed by RxSight Inc.
- SEC Form 10-Q filed by RxSight Inc.
- RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RxSight, Inc. Reports Third Quarter 2026 Results
- Amendment: SEC Form SCHEDULE 13G/A filed by RxSight Inc.
- RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
- RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
- RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
- K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world